emirates7 - Ovasave, a FemTech startup based in Abu Dhabi and part of the Hub71 ecosystem, has successfully raised $1.2 million in a pre-seed funding round aimed at advancing fertility and hormonal health solutions. The investment was secured from a combination of regional and international backers, including lead investors PlusVC, Annex Investments, and New York’s 25 Madison, along with strategic angel investors and family offices from the UAE and Saudi Arabia.
The funds will be allocated to expanding Ovasave’s presence across the GCC, strengthening corporate collaborations, and launching the next version of its mobile application. The app’s upcoming features include menstrual tracking, symptom logging, healthcare access, and AI-powered treatment plans.
This fundraising milestone coincides with the UAE’s broader healthcare and women’s rights reforms, creating favorable conditions for FemTech innovation. As a startup licensed by the Department of Health – Abu Dhabi and supported by Hub71, Ovasave is strategically aligned with the country’s emphasis on digital and preventive healthcare.
Majd Abu Zant, Ovasave’s Co-founder, emphasized Abu Dhabi’s supportive environment for startups, noting the advantages of its innovation-driven infrastructure, funding accessibility, and proximity to key decision-makers. He stated that these factors make it an ideal launchpad for high-impact ventures, as the company prepares to enter the Saudi market and scale across MENA.
Co-founder and CEO Torkia Mahloul highlighted the urgent need for better access and early intervention in women’s health, especially in the areas of fertility and hormones. She described the funding as a significant milestone in Ovasave’s mission to transform the women’s healthcare landscape in the region.
With a strong focus on proactive care, Ovasave aims to lower healthcare costs, improve patient outcomes, and tackle the stigma surrounding women’s reproductive health. The startup’s momentum comes at a time of rising investor interest in FemTech, with plans to expand into Saudi Arabia this summer and broader MENA growth as part of its three-year roadmap.
According to FemTech Analytics, the MENA FemTech market is expected to hit $3.8 billion by 2031, growing at an annual rate of 15% between 2021 and 2031—indicating strong future potential for innovators like Ovasave.
The funds will be allocated to expanding Ovasave’s presence across the GCC, strengthening corporate collaborations, and launching the next version of its mobile application. The app’s upcoming features include menstrual tracking, symptom logging, healthcare access, and AI-powered treatment plans.
This fundraising milestone coincides with the UAE’s broader healthcare and women’s rights reforms, creating favorable conditions for FemTech innovation. As a startup licensed by the Department of Health – Abu Dhabi and supported by Hub71, Ovasave is strategically aligned with the country’s emphasis on digital and preventive healthcare.
Majd Abu Zant, Ovasave’s Co-founder, emphasized Abu Dhabi’s supportive environment for startups, noting the advantages of its innovation-driven infrastructure, funding accessibility, and proximity to key decision-makers. He stated that these factors make it an ideal launchpad for high-impact ventures, as the company prepares to enter the Saudi market and scale across MENA.
Co-founder and CEO Torkia Mahloul highlighted the urgent need for better access and early intervention in women’s health, especially in the areas of fertility and hormones. She described the funding as a significant milestone in Ovasave’s mission to transform the women’s healthcare landscape in the region.
With a strong focus on proactive care, Ovasave aims to lower healthcare costs, improve patient outcomes, and tackle the stigma surrounding women’s reproductive health. The startup’s momentum comes at a time of rising investor interest in FemTech, with plans to expand into Saudi Arabia this summer and broader MENA growth as part of its three-year roadmap.
According to FemTech Analytics, the MENA FemTech market is expected to hit $3.8 billion by 2031, growing at an annual rate of 15% between 2021 and 2031—indicating strong future potential for innovators like Ovasave.